Blunting effect of hypoxia on the proliferation and differentiation of human primary and rat L6 myoblasts is not counteracted by Epo

Cell Proliferation

Volumn 43, Issue 1, 2010, Pages 1-8

  Launay, T ^a,b   Hagstrom L ^a   Lottin Divoux, S ^a   Marchant, D ^a   Quidu, P ^a   Favret, F ^a   Duvallet, A ^a   Darribere T ^c   Richalet, J P ^a   Beaudry, M ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Sorbonne Universités   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA; MYOGENIN; MYOSIN HEAVY CHAIN; OXYGEN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIA; IN VITRO STUDY; MYOBLAST; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KINETICS; MYOBLASTS; MYOGENIN; MYOSIN HEAVY CHAINS; RATS; RECEPTORS, ERYTHROPOIETIN;

RATTUS;

EID: 73349090906     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2009.00648.x     Document Type: Article

References (24)

1. Preedy VR, Smith DM, Sugden PH (1985) The effects of 6 hours of hypoxia on protein synthesis in rat tissues in vivo and in vitro. Biochem. J. 228, 179 185.
2. Scholz D, Thomas S, Sass S, Podzuweit T (2003) Angiogenesis and myogenesis as two facets of inflammatory post-ischemic tissue regeneration. Mol. Cell. Biochem. 246, 57 67.
3. Yun Z, Lin Q, Giaccia AJ (2005) Adaptive myogenesis under hypoxia. Mol. Cell. Biol. 25, 3040 3055.
4. Chakravarthy MV, Spangenburg EE, Booth FW (2001) Culture in low levels of oxygen enhances in vitro proliferation potential of satellite cells from old skeletal muscles. Cell. Mol. Life Sci. 58, 1150 1158.
5. Di Carlo A, De Mori R, Martelli F, Pompilio G, Capogrossi MC, Germani A (2004) Hypoxia inhibits myogenic differentiation through accelerated MyoD degradation. J. Biol. Chem. 279, 16332 16338.
6. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC et al. (1993) Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 44, 1149 1162.
7. Maiese K, Li F, Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293, 90 95.
8. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 87, 5978 5982.
9. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M et al. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA 95, 4635 4640.
10. Scoppetta C, Grassi F (2004) Erythropoietin: a new tool for muscle disorders? Med. Hypotheses 63, 73 75.
11. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT et al. (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J. Biol. Chem. 275, 39754 39761.
12. Rotter R, Menshykova M, Winkler T, Matziolis G, Stratos I, Schoen M et al. (2008) Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue. J. Orthop. Res. 26, 1618 1626.
13. Lundby C, Hellsten Y, Jensen MB, Munch AS, Pilegaard H (2008) Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J. Appl. Physiol. 104, 1154 1160.
14. Kitzmann M, Bonnieu A, Duret C, Vernus B, Barro M, Laoudj-Chenivesse D et al. (2006) Inhibition of Notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells. J. Cell. Physiol. 208, 538 548.
15. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM et al. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107, 1892 1895. (Pubitemid 43289368)
16. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J et al. (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617 628.
17. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H (2004) The role of erythropoietin in regulating angiogenesis. Dev. Biol. 276, 101 110.
18. Wagner KF, Katschinski DM, Hasegawa J, Schumacher D, Meller B, Gembruch U et al. (2001) Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97, 536 542.
19. Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc. Res. 59, 538 548.
20. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr., Tabira T et al. (1993) Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J. Biol. Chem. 268, 11208 11216.
21. Lappin TR, Maxwell AP, Johnston PG (2002) EPO's alter ego: erythropoietin has multiple actions. Stem Cells 20, 485 492.
22. Todokoro K, Kuramochi S, Nagasawa T, Abe T, Ikawa Y (1991) Isolation of a cDNA encoding a potential soluble receptor for human erythropoietin. Gene 106, 283 284.
23. Chanseaume S, Azarnoush K, Maurel A, Bellamy V, Peyrard S, Bruneval P et al. (2007) Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium? Interact. Cardiovasc. Thorac. Surg. 6, 293 297.
24. Cayla JL, Maire P, Duvallet A, Wahrmann JP (2008) Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative. Int. J. Sports Med. 29, 460 465.